SignalPoint Asset Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-6,565
Closed -$215K 248
2023
Q4
$215K Buy
+6,565
New +$179K 0.06% 210
2023
Q3
Sell
-6,675
Closed -$228K 213
2023
Q2
$228K Hold
6,675
0.07% 195
2023
Q1
$201K Buy
+6,675
New +$207K 0.06% 211
2022
Q4
Sell
-6,660
Closed -$218K 219
2022
Q3
$218K Sell
6,660
-7
-0.1% -$257 0.08% 192
2022
Q2
$209K Sell
6,667
-65
-1% -$2.27K 0.08% 199
2022
Q1
$309K Buy
6,732
+2
+0% +$95 0.1% 179
2021
Q4
$412K Sell
6,730
-2,426
-26% -$168K 0.13% 150
2021
Q3
$684K Buy
9,156
+776
+9% +$65.1K 0.22% 102
2021
Q2
$775K Sell
8,380
-4,011
-32% -$341K 0.25% 95
2021
Q1
$1.1M Buy
12,391
+7,463
+151% +$740K 0.39% 69
2020
Q4
$460K Buy
4,928
+1,478
+43% +$118K 0.17% 119
2020
Q3
$220K Buy
+3,450
New +$202K 0.09% 175

Other funds holding ARKG

SignalPoint Asset Management's ARKG Position: Q1 2024 in Review

SignalPoint Asset Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2024, closing a stake of 6,565 shares — an estimated $215K sold.

SignalPoint Asset Management first reported a position in ARKG in Q3 2020 and held it in 12 quarters. The position peaked at $1.1M in Q1 2021. 284 funds tracked by Wall St. Rank hold ARKG as of Q1 2024.

  • SignalPoint Asset Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2024 after selling out during the quarter.
  • SignalPoint Asset Management sold 6,565 ARK Genomic Revolution ETF shares in Q1 2024, an estimated $215K.
  • SignalPoint Asset Management first reported a position in ARK Genomic Revolution ETF in Q3 2020 and held it in 12 quarters.
  • SignalPoint Asset Management's ARK Genomic Revolution ETF position peaked at $1.1M in Q1 2021.
  • 284 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2024.

Based on SignalPoint Asset Management's 13F filing for Q1 2024, filed 11 Apr 2024.